Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) have been given an average recommendation of “Buy” by the sixteen research firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $69.50.

A number of research firms have recently commented on AERI. Mizuho reissued a “buy” rating on shares of Aerie Pharmaceuticals in a report on Friday, November 3rd. Guggenheim began coverage on Aerie Pharmaceuticals in a report on Monday, October 23rd. They set a “buy” rating and a $80.00 price target for the company. Zacks Investment Research raised Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th. Needham & Company LLC reissued a “buy” rating and set a $76.00 price target (up previously from $65.00) on shares of Aerie Pharmaceuticals in a report on Monday, October 16th. Finally, Canaccord Genuity reissued a “positive” rating and set a $73.00 price target (up previously from $65.00) on shares of Aerie Pharmaceuticals in a report on Monday, October 16th.

Aerie Pharmaceuticals (NASDAQ:AERI) traded up $1.90 during trading on Monday, hitting $64.25. The stock had a trading volume of 325,446 shares, compared to its average volume of 514,243. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78. Aerie Pharmaceuticals has a 12 month low of $35.20 and a 12 month high of $66.25.

Hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. grew its position in Aerie Pharmaceuticals by 11.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock worth $140,000 after acquiring an additional 275 shares during the last quarter. Quantbot Technologies LP grew its position in Aerie Pharmaceuticals by 792.5% during the 3rd quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock worth $144,000 after acquiring an additional 2,647 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in Aerie Pharmaceuticals by 2,711.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after acquiring an additional 3,579 shares during the last quarter. Amalgamated Bank bought a new stake in Aerie Pharmaceuticals during the 2nd quarter worth $204,000. Finally, Palisade Capital Management LLC NJ bought a new stake in Aerie Pharmaceuticals during the 2nd quarter worth $212,000.

TRADEMARK VIOLATION WARNING: “Aerie Pharmaceuticals, Inc. (AERI) Receives $69.50 Consensus Price Target from Analysts” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.watchlistnews.com/aerie-pharmaceuticals-inc-aeri-receives-69-50-consensus-price-target-from-analysts/1736022.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.